... New research adds to growing evidence that biosimilars — lower-cost alternatives to biologic drugs — may be an effective long-term treatment for moderate to severe psoriasis.A recent study followed 1,195 people treated with SB5 (adalimumab-bwwd or Hadlima), a biosimilar to adalimumab (Humira), for up to four years. ...
... New research adds to growing evidence that biosimilars — lower-cost alternatives to biologic drugs — may be an effective long-term treatment for moderate to severe psoriasis.A recent study followed 1,195 people treated with SB5 (adalimumab-bwwd or Hadlima), a biosimilar to adalimumab (Humira), for up to four years. ...
... These include: Adalimumab-adbm (Cyltezo) — The only interchangeable biosimilar approved so far Adalimumab-afzb (Abrilada) Adalimumab-atto (Amjevita) Adalimumab-bwwd (Hadlima) Adalimumab-fkjp (Hulio) Adalimumab-adaz (Hyrimoz) Adalimumab-aqvh (Yusimry) Researchers have at least three more biosimilars in the works, offering people with PsA several treatment ...
... These include: Adalimumab-adbm (Cyltezo) — The only interchangeable biosimilar approved so far Adalimumab-afzb (Abrilada) Adalimumab-atto (Amjevita) Adalimumab-bwwd (Hadlima) Adalimumab-fkjp (Hulio) Adalimumab-adaz (Hyrimoz) Adalimumab-aqvh (Yusimry) Researchers have at least three more biosimilars in the works, offering people with PsA several treatment ...